Healthcare / BiotechnologyKOSDAQ
$3790.00
-140.00 (-3.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-6.3B · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-19.5%
↓Gross Margin
73.7%
↑Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+81.4%
FCF CAGR
—
FCF margin
-9.1%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.29B · net income $-6.33B · FCF $-6.34B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $69.29B | $69.29B | $68.36B | $33.14B | $11.61B |
| Net Income | $-6.33B | $-6.33B | $-5.30B | $-13.85B | $-21.92B |
| EBITDA | $-3.66B | $-3.66B | $-441.8M | $-11.64B | $-20.44B |
| EPS | -326.00 | -326.00 | -276.00 | -748.00 | -1305.00 |
| Gross Margin | 73.7% | 73.7% | 68.5% | 71.6% | 69.1% |
| Operating Margin | -13.9% | -13.9% | -10.1% | -55.7% | -174.8% |
| Net Margin | -9.1% | -9.1% | -7.8% | -41.8% | -188.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.44 | 0.41 | 0.18 |
| Current Ratio | 3.91 | 3.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.34B | $-6.34B | $-6.00B | $-29.39B | $-31.32B |
| Returns | |||||
| ROE | -19.5% | -19.5% | -14.0% | -30.8% | -28.4% |
| Valuation | |||||
| P/B | 2.27 | 2.27 | 2.84 | 4.99 | 2.36 |
| Growth & Yield | |||||
| Revenue Growth | 1.4% | 1.4% | 106.3% | 185.5% | — |
| EPS Growth | -18.1% | -18.1% | 63.1% | 42.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-276.00 → -326.00
Residual
-19.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.